• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis Evaluation of Novel Antigen-Based Rapid Detection Test for the Diagnosis of SARS-CoV-2 in Respiratory Samples

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2020 Jun 1;S1201-9712(20)30405-7.
doi: 10.1016/j.ijid.2020.05.098. Online ahead of print.
Evaluation of Novel Antigen-Based Rapid Detection Test for the Diagnosis of SARS-CoV-2 in Respiratory Samples


Lorena Porte[SUP] 1 [/SUP], Paulette Legarraga[SUP] 2 [/SUP], Valeska Vollrath[SUP] 2 [/SUP], Ximena Aguilera[SUP] 3 [/SUP], Jos? M Munita[SUP] 4 [/SUP], Rafael Araos[SUP] 4 [/SUP], Gabriel Pizarro[SUP] 2 [/SUP], Pablo Vial[SUP] 5 [/SUP], Mirentxu Iruretagoyena[SUP] 2 [/SUP], Sabine Dittrich[SUP] 6 [/SUP], Thomas Weitzel[SUP] 7 [/SUP]



Affiliations

Abstract

Objectives: In the context of the Covid-19 pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority. We evaluated a novel rapid antigen detection test (RDT) for SARS-CoV-2 in respiratory samples.
Methods: The fluorescence immunochromatographic SARS-CoV-2 antigen test (Bioeasy Biotechnology Co., Shenzhen, China) was evaluated using universal transport medium with nasopharyngeal (NP) and oropharyngeal (OP) swabs from suspected Covid-19 cases. Diagnostic accuracy was determined in comparison to SARS-CoV-2 real time (RT)-PCR.
Results: A total of 127 samples were included; 82 were RT-PCR positive. Median patients' age was 38 years, 53.5% were male, and 93.7% were from the first week after symptom onset. Overall sensitivity and specificity were 93.9% (CI95% 86.5-97.4) and 100% (CI95% 92.1-100), respectively, with a diagnostic accuracy of 96.1% and Kappa coefficient of 0.9. Sensitivity was significantly higher in samples with high viral loads.
Conclusions: The evaluated RDT showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads, despite the use of a non-validated sample material. The assay has the potential to become an important tool for early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods.

Keywords: Coronavirus; Covid-19; SARS-CoV-2; antigen; diagnosis; rapid diagnostic test.



Copyright ? 2020. Published by Elsevier Ltd.
 
Back
Top Bottom